Abstract Number: 1468 • ACR Convergence 2021
Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model
Background/Purpose: A suspension of empty large multilamellar vesicles (MLV) liposomes composed of dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC), is currently under clinical development for symptomatic knee…Abstract Number: 1180 • 2019 ACR/ARP Annual Meeting
Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study
Background/Purpose: Sprifermin is under investigation as a potential disease-modifying osteoarthritis drug (DMOAD). 2-yr results from the FORWARD study showed significant dose-dependent modification of cartilage thickness…Abstract Number: 1325 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA
Background/Purpose: The disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) is a key enzyme in OA (Verma P, et al. J Cell Biochem 2011;112:3507-14). In preclinical models…Abstract Number: 2761 • 2019 ACR/ARP Annual Meeting
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
Background/Purpose: Results from the 5-year Phase II FORWARD study showed significant dose-dependent modification of total femorotibial joint (TFTJ) cartilage thickness change with sprifermin at 2…Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…Abstract Number: 1366 • 2018 ACR/ARHP Annual Meeting
Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
Background/Purpose: SM04690, a small molecule, intra-articular (IA) Wnt pathway inhibitor, is in development for knee OA treatment. A phase 2, 52-week, trial evaluated changes in…Abstract Number: 429 • 2018 ACR/ARHP Annual Meeting
The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor Miv-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis Initiative
Background/Purpose: New imaging biomarkers using supervised machine learning offer opportunities to demonstrate effects of potential DMOADs on joint structure in short, small trials based on…Abstract Number: 436 • 2018 ACR/ARHP Annual Meeting
Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
Background/Purpose: Sprifermin, a recombinant human fibroblast growth factor 18, is currently being investigated as a potential disease-modifying OA drug. Sprifermin treatment leads to a dose-dependent…Abstract Number: 1356 • 2018 ACR/ARHP Annual Meeting
Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA
Background/Purpose: Osteoarthritis (OA) is characterized by structural changes of the joint, of which degradation of articular cartilage is one of the major signs1. The main…Abstract Number: 1364 • 2018 ACR/ARHP Annual Meeting
Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved…Abstract Number: 1L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Background/Purpose: Sprifermin, a novel recombinant human fibroblast growth factor-18 is currently investigated as a potential disease-modifying osteoarthritis (OA) drug. Two-year primary data from a 5-year…Abstract Number: 14L • 2017 ACR/ARHP Annual Meeting
Miv-711, a Novel Cathepsin K Inhibitor Demonstrates Evidence of Osteoarthritis Structure Modification: Results from a 6 Month Randomized Double-Blind Placebo-Controlled Phase IIA Trial
Background/Purpose: The need for drugs that achieve structure modification in OA is imminent but their development has been burdened by the need for large, long…Abstract Number: 1207 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Structural Measures in Knee Osteoarthritis: Baseline Values and Change from Baseline Discriminate Patients Subsequently Receiving Knee Replacement
Background/Purpose: Structural measures of knee OA (KOA) progression include assessment of radiographic joint space width (JSW) and quantitative MRI (qMRI) measurement of cartilage thickness, both…Abstract Number: 2183 • 2017 ACR/ARHP Annual Meeting
Two-Year Changes in Knee Osteoarthritis Symptoms: Comparing Clinical Relevance of Patient-Reported Outcomes By Anchoring to Knee Replacement
Background/Purpose: Randomized controlled trials (RCTs) of interventions for knee OA (KOA) may include a patient-reported outcome (PRO) measure as a primary endpoint. Several measures of…Abstract Number: 1151 • 2015 ACR/ARHP Annual Meeting
The Proteomic Profile of Histological Samples Derived from a Surgical Mouse Model of Osteoarthritis Reveals an Unexpected Mode of Action for the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017
Background/Purpose : CRB0017 is a novel therapeutic monoclonal antibody that recognizes the spacer domain of aggrecanase-2, a key enzyme in the degradation of extracellular matrix…
ACR Meeting Abstracts